CDXS
Price
$2.50
Change
-$0.00 (-0.00%)
Updated
Jun 26, 01:13 PM (EDT)
Capitalization
207.94M
35 days until earnings call
VCEL
Price
$41.76
Change
-$1.58 (-3.65%)
Updated
Jun 26, 01:43 PM (EDT)
Capitalization
2.11B
34 days until earnings call
Interact to see
Advertisement

CDXS vs VCEL

Header iconCDXS vs VCEL Comparison
Open Charts CDXS vs VCELBanner chart's image
Codexis
Price$2.50
Change-$0.00 (-0.00%)
Volume$1.72K
Capitalization207.94M
Vericel
Price$41.76
Change-$1.58 (-3.65%)
Volume$100
Capitalization2.11B
CDXS vs VCEL Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. VCEL commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a StrongBuy and VCEL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (CDXS: $2.51 vs. VCEL: $41.88)
Brand notoriety: CDXS and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 72% vs. VCEL: 72%
Market capitalization -- CDXS: $207.94M vs. VCEL: $2.11B
CDXS [@Biotechnology] is valued at $207.94M. VCEL’s [@Biotechnology] market capitalization is $2.11B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, CDXS is a better buy in the long-term than VCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 4 TA indicator(s) are bullish while VCEL’s TA Score has 5 bullish TA indicator(s).

  • CDXS’s TA Score: 4 bullish, 4 bearish.
  • VCEL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CDXS and VCEL are a good buy in the short-term.

Price Growth

CDXS (@Biotechnology) experienced а +6.81% price change this week, while VCEL (@Biotechnology) price change was +0.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.78%. For the same industry, the average monthly price growth was +31.36%, and the average quarterly price growth was +15.04%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 31, 2025.

VCEL is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+1.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCEL($2.11B) has a higher market cap than CDXS($208M). VCEL YTD gains are higher at: -23.730 vs. CDXS (-47.379). VCEL has higher annual earnings (EBITDA): 10.6M vs. CDXS (-62.28M). VCEL has more cash in the bank: 113M vs. CDXS (59.8M). CDXS has less debt than VCEL: CDXS (59.5M) vs VCEL (99M). VCEL has higher revenues than CDXS: VCEL (239M) vs CDXS (49.8M).
CDXSVCELCDXS / VCEL
Capitalization208M2.11B10%
EBITDA-62.28M10.6M-588%
Gain YTD-47.379-23.730200%
P/E RatioN/A837.60-
Revenue49.8M239M21%
Total Cash59.8M113M53%
Total Debt59.5M99M60%
FUNDAMENTALS RATINGS
CDXS vs VCEL: Fundamental Ratings
CDXS
VCEL
OUTLOOK RATING
1..100
195
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
9888
PRICE GROWTH RATING
1..100
6460
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CDXS's Valuation (46) in the Chemicals Specialty industry is somewhat better than the same rating for VCEL (97) in the Medical Specialties industry. This means that CDXS’s stock grew somewhat faster than VCEL’s over the last 12 months.

VCEL's Profit vs Risk Rating (59) in the Medical Specialties industry is somewhat better than the same rating for CDXS (100) in the Chemicals Specialty industry. This means that VCEL’s stock grew somewhat faster than CDXS’s over the last 12 months.

VCEL's SMR Rating (88) in the Medical Specialties industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

VCEL's Price Growth Rating (60) in the Medical Specialties industry is in the same range as CDXS (64) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

VCEL's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that VCEL’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSVCEL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 7 days ago
83%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 10 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THLCX22.390.08
+0.36%
Thrivent Large Cap Growth S
JLGMX87.11N/A
N/A
JPMorgan Large Cap Growth R6
PSMVX11.01N/A
N/A
Principal SmallCap Value II R6
AMAFX9.86N/A
N/A
American Century Small Cap Dividend I
RREAX28.91-0.50
-1.70%
Russell Inv Global Real Estate Secs A

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+0.40%
BEAM - CDXS
49%
Loosely correlated
-2.27%
PRAX - CDXS
49%
Loosely correlated
-1.43%
DNLI - CDXS
49%
Loosely correlated
+0.35%
CRSP - CDXS
47%
Loosely correlated
+1.88%
ABCL - CDXS
46%
Loosely correlated
+3.26%
More

VCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCEL
1D Price
Change %
VCEL100%
-3.37%
VCYT - VCEL
52%
Loosely correlated
-1.60%
MNMD - VCEL
47%
Loosely correlated
-4.27%
BEAM - VCEL
43%
Loosely correlated
-2.27%
SYRE - VCEL
41%
Loosely correlated
+2.01%
CDXS - VCEL
40%
Loosely correlated
+0.40%
More